Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. Issue 11 (17th July 2018)

• Record Type: Journal Article
• Authors: Wedekind, Mary Frances; Haworth, Kellie B.; Arnold, Michael; Stanek, Joseph R.; Lee, Dean; Cripe, Timothy P.
• Is Part Of: Pediatric blood & cancer. Volume 65:Issue 11(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-07-17
• Subjects: DSRCT -- immune profile -- immunohistochemistry -- synovial sarcoma; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.27313
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: Desmoplastic small round cell tumor (DSRCT) and synovial sarcoma are rare tumors with dismal outcomes requiring new therapeutic strategies. Immunotherapies have shown promise in several cancer types, but have not been evaluated in DSRCT and synovial sarcoma. Because the immune microenvironment can provide indications of the inflammatory nature of tumors, immunohistochemical staining is able to assess the tumor immune infiltrates in both tumor types. Procedure: Using tissue microarrays of DSRCT and synovial sarcoma tumor samples, we detected tumoral HLA‐A/B/C, beta‐2‐microglobulin(B2M), and PD‐L1 expression, and quantified tumor‐infiltrating lymphocytes expressing CD4, CD8, CD56, CD45RO, or FOXP3 by immunohistochemistry. We used staining intensity on a scale of 0–3 and percentage of tumor stained to determine HLA, B2M, and PD‐L1 scores. We calculated the cytotoxic T lymphocyte (CTL) target score as HLA score × B2M score/100. Results: In diagnostic samples, we found high HLA and CTL target scores and low PD‐L1 expression with decreased scores in recurrence for both tumor types. We found an increase in CD56 + natural killer cells in DSRCT samples from diagnosis to recurrence. Conclusions: We found similar immunostimulatory profiles in DSRCT and synovial sarcoma. Our findings suggest that DSRCT and synovial sarcoma may be amenable to immunotherapies, albeit there was significant heterogeneity. Interestingly, HLA and CTL target scores decreased at recurrence, possibly reflecting immunoevasion. Our findings suggest both tumor types may be amendable to CTL‐based therapies at diagnosis but less so at relapse. Our results support further investigation into the prognostic and predictive value of these findings in a larger dataset.